EUCTR2019-001605-24-GB进行中（未招募）1 期
An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome
GW Research Ltd0 个研究点目标入组 252 人开始时间: 2019年10月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 252
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the trial, patients must fulfil all of the following criteria:
- •Patient has completed all scheduled visits of the treatment phase of the RCT, GWND18064, and has transitioned to OLE by the point of RCT follow-up (Visit 11).
- •Patient (if possessing adequate understanding, in the investigator’s opinion) and/or the patient’s parent(s)/legal representative is willing and able to give informed consent/assent for participation in the trial.
- •Patient and the patient’s caregiver are willing and able (in the investigator’s opinion) to comply with all trial requirements (including the completion of all caregiver assessments by the same caregiver throughout the trial).
- •Patient must have the ability to swallow the investigational medicinal product (IMP) provided as a liquid solution or the ability for the IMP to be delivered via gastrostomy (G) or nasogastric (NG) feeding tube (only G- or NG-tubes made from polyurethane or silicon are allowed).
- •Patient and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
- •Patient and/or parent(s)/legal representative is willing to allow the patient’s primary care practitioner (if the patient has one) and consultant (if the patient has one) to be notified of participation in the trial if the primary care practitioner/consultant is different from the investigator.
- •Per Protocol Annex 1, with the exception of the inclusion criterion that requires patients must have completed all scheduled visits of the treatment phase of the RCT, GWND18064, and transitioned to OLE by the point of RCT follow-up (Visit 11), all inclusion and exclusion criteria defined in the GWND19002 protocol must be met. In addition, the following inclusion criteria apply:
- •Inclusion criteria
- •Patient has completed all scheduled visits of the treatment phase of the RCT, either in clinic or completed as many scheduled assessments as feasible remotely, or has withdrawn from GWND18064 after discussion with the medical monitor due to inability to adequately monitor safety and benefit risk.
- •Visit 1 is taking place no later than 3 months after screening of new subjects for study GWND18064 has reopened at their trial site.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 252
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •The patient may not enter the trial if ANY of the following apply:
- •Patient meets the withdrawal criteria (including clinically significant abnormal laboratory values), in the investigator’s opinion.
- •Patient met during the RCT the criteria for permanent IMP discontinuation (unless in case of an AE, if AE was not considered related with the IMP; patients that met alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations discontinuation criteria must be excluded).
- •Females of childbearing potential, unless willing to ensure that they or their partner use a highly effective method of birth control (e.g., combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal or transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable or implantable ] intrauterine devices/hormone-releasing systems , bilateral tubal occlusion, vasectomized partner, sexual abstinence during the trial and for 3 months after the last dose.
- •Patient has been previously enrolled and dosed in this trial.
- •Patient is unwilling to abstain from donation of blood during the trial.
- •Male participants who are fertile (i.e., after puberty unless permanently sterile by bilateral orchidectomy) and with a partner of childbearing potential unless agree to ensure that they use male contraception (e.g., condom) or remain sexually abstinent during the trial and for 3?months after the last dose.
- •Per Protocol Annex 1, with the exception of the inclusion criterion that requires patients must have completed all scheduled visits of the treatment phase of the RCT, GWND18064, and transitioned to OLE by the point of RCT follow-up (Visit 11), all inclusion and exclusion criteria defined in the GWND19002 protocol must be met. In addition, the following exclusion criteria apply:
- •Any history of suicidal behavior or any suicidal ideation in the last month or at Visit 1.
- •Patient has clinically relevant abnormalities in the electrocardiogram measured at Visit 1 (including QT interval, corrected by Bazett's correction formula [QTcB] > 450 msec, average of 3 measurements).
- •Patient has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP (active and placebo), such as sesame oil.
- •Patient has moderately impaired hepatic function at screening, defined as serum ALT or AST > 3 × ULN or total bilirubin [TBL] > 2 × ULN.
- •This criterion can only be confirmed once the Visit 1 laboratory results are available. If Visit 1 laboratory results indicate the patient is not eligible, the patient must be withdrawn. Prior to withdrawal for the transaminase elevations noted above, the investigator may choose to confirm the transaminase elevations by repeating the following laboratory tests within 24 to 48 hours: ALT, AST, TBL, international normalized ratio, % eosinophils, gamma-glutamyl transferase, alkaline phosphatase, and eosinophils. Should the above transaminase elevation criteria be confirmed, the patient must be withdrawn from the trial.
- •Patient has received an IMP (other than GWND18064 IMP) since participation in GWND18064.
- •Patient has been taking felbamate for less than 1 year prior to Visit 1
- •Patient is currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex
- •® [nabiximols]) or cannabidiol oral solutions (excluding GWND18064 IMP) within the 3
研究者
相似试验
进行中（未招募）
1 期
An open label extension study for long-term safety of GWP42003-P in patients with Rett SyndromeEUCTR2019-001605-24-ITGW RESEARCH LTD.252
进行中（未招募）
1 期
An open label extension study for long-term safety of GWP42003-P in patients with Rett SyndromeRett syndrome (RTT) [typical or atypical]MedDRA version: 20.0Level: PTClassification code 10077709Term: Rett syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-001605-24-ESGW Research Ltd21
进行中（未招募）
1 期
An open-label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndromeRestless Leg's SyndromeMedDRA version: 7.0Level: LLTClassification code 10058920EUCTR2005-002611-25-ESSchwarz Biosciences GmbH510
进行中（未招募）
不适用
An open-label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndromeRestless Leg's SyndromeMedDRA version: 7.0Level: LLTClassification code 10058920EUCTR2005-002611-25-ATSchwarz Biosciences GmbH420
进行中（未招募）
不适用
An open-label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndromeEUCTR2005-002611-25-DESchwarz Biosciences GmbH420